drugset / Trial / NCT05125471
Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this open-label study is to evaluate the safety and efficacy of cobimetinib in extracranial AVM.
Timeline
- Start
- 2022-07-26
- Primary completion
- 2025-09-03
- Completion
- 2025-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobimetinib | Small molecule | 1 mg/kg | — |
| Subject | Cobimetinib | Small molecule | 60 mg | — |